Atea Pharmaceuticals, Inc.AVIRNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+38.4%
5Y CAGR+52.9%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+38.4%/yr
vs +63.8%/yr prior
5Y CAGR
+52.9%/yr
Recent deceleration
Acceleration
-25.4pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
8.4x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $180.89M | +65.1% |
| 2024 | $109.58M | +16.5% |
| 2023 | $94.07M | +37.8% |
| 2022 | $68.26M | +49.1% |
| 2021 | $45.78M | +111.6% |
| 2020 | $21.64M | +48.1% |
| 2019 | $14.61M | +54.1% |
| 2018 | $9.48M | - |